TriSalus promotes James Young to CFO; appoints new CCO and Chief of Clinical Operations

TriSalus Life Sciences, Inc.

James Young promoted to CFO, effective Jan 6, 2025; annual base salary $420k, target bonus 50%.
Sean Murphy transitions to Chief Manufacturing, Strategy and Business Development Officer; remains on board.
Richard Marshak appointed Chief Commercial Officer; Jodi Devlin appointed Chief of Clinical Operations.
Executive officers elected to forgo $515k in salary for RSUs under new Salary Investment Program.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

James Young

Chief Financial Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-01-06
Filed: January 8, 2025, 6:59 PM ET

promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company

Role change

Sean Murphy

Chief Manufacturing, Strategy and Business Development Officer

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-01-06
Filed: January 8, 2025, 6:59 PM ET

appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Young changed role as Chief Financial Officer at TriSalus Life Sciences, Inc..

Action: promoted
Role: Chief Financial Officer

Exact text from the filing

promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sean Murphy was appointed as Chief Manufacturing, Strategy and Business Development Officer at TriSalus Life Sciences, Inc..

Action: appointed
Role: Chief Manufacturing, Strategy and Business Development Officer

Exact text from the filing

appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer

View on SEC.gov

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-002023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.